CARBALIVE

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Abstract

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.

Project details

Unibo Team Leader: Paolo Caraceni

Unibo involved Department/s:
Dipartimento di Scienze Mediche e Chirurgiche

Coordinator:
Ucl University College London(United Kingdom)

Other Participants:
Mast Carbon International Ltd (United Kingdom)
Alpha Bioresearch Sl (Spain)
Assistance Publique - Hopitaux De Paris (France)
Servicio Madrileǹo De Salud (Spain)
Yaqrit Limited (United Kingdom)
A2f Associates Limited (United Kingdom)
Università  degli Studi di PADOVA (Italy)
Institut Catala De La Salut (Spain)
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Idibaps (Spain)
ALMA MATER STUDIORUM - Università di Bologna (Italy)
Faculdade De Medicina Da Universidade De Lisboa (Portugal)
Universitat Bern (Switzerland)
University Of Brighton (United Kingdom)

Total Eu Contribution: Euro (EUR) 5.913.079,75
Project Duration in months: 69
Start Date: 01/05/2015
End Date: 31/01/2021

Cordis webpage
Project website

Good health and well-being This project contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.

UE flag This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634579